CMD
$45.10
Cantel Medical
$1.80
4.16%
Earnings Details
3rd Quarter April 2020
Thursday, June 4, 2020 7:00:00 AM
Tweet Share Watch
Summary

Cantel Medical Beats

Cantel Medical (CMD) reported 3rd Quarter April 2020 earnings of $0.16 per share on revenue of $236.9 million. The consensus earnings estimate was $0.14 per share on revenue of $236.0 million. The Earnings Whisper number was for a loss of $0.03 per share. Revenue grew 3.7% on a year-over-year basis.

Results
Reported Earnings
$0.16
Earnings Whisper
($0.03)
Consensus Estimate
$0.14
Reported Revenue
$236.9 Mil
Revenue Estimate
$236.0 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Cantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2020

LITTLE FALLS, N.J., June 4, 2020 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its third quarter ended April 30, 2020.

Third quarter 2020 net sales were $236.9M, up 3.7% compared to the prior year. Excluding the impact from foreign currency, net sales increased by 4.2%, primarily driven by the impact from acquisitions of 15.5% offset by an organic decline of 11.3%. The decline in organic sales was a result of the reduction of elective procedures driven by the worldwide COVID pandemic, which largely impacted the last five weeks of the Company's fiscal quarter. The pandemic primarily impacted the Company's Medical and Dental segments during this period.

Third quarter 2020 GAAP earnings per diluted share increased 85.0% to $0.37, compared to GAAP earnings per diluted share of $0.20 in the prior year period. While GAAP earnings per diluted share was negatively impacted by COVID and higher amortization in the period, the impacts were offset by a favorable fair value adjustment to a Hu-Friedy earnout liability.

Third quarter 2020 non-GAAP earnings per diluted share decreased 70.9% to $0.16, compared to non-GAAP earnings per diluted share of $0.55 in the prior year period. The decrease in earnings per share was driven by the impact from COVID, which significantly impacted the Company's Medical and Dental segment revenue for the last five weeks of the quarter.

George Fotiades, President and Chief Executive Officer, stated, "The impact from the COVID pandemic has been historic for the industry, our customers, patients and our Company. I am proud of how our Company has operated through these challenges and expect that we will be in a strong position to serve our customers during the recovery. Our mission in Infection Prevention has never been more critical, as we continue to support those on the front lines of this pandemic by supplying much needed PPE, disinfectant chemistry, and other infection prevention solutions to those who need it most."

With the acquisition of Hu-Friedy and the impact from COVID, the Company's balance sheet has changed from historical trends. The third quarter ended with cash of $115.8M and gross debt of $976.9M, while generating EBITDAS of $43.5M and adjusted EBITDAS of $31.7M in the quarter, down 23.3%.

In the weeks following the end of its third quarter, the Company has made significant progress in solidifying its financial position. On May 11th, 2020, the Company entered into an agreement to amend its credit facilities with its lender group providing ample flexibility to manage the expected impacts of the current environment created by the COVID pandemic. Following the amendment, the Company announced the sale of $168M in aggregate value of its private offering of Convertible Senior Notes due 2025. This offering provides additional liquidity that helps enable the Company to continue to weather the pandemic, while remaining strongly positioned for the expected post-COVID recovery.

Third quarter financial results and key updates:

  • Strong Life Sciences revenue performance with organic growth of +7.3% for the quarter driven by COVID-related demand for portable water systems
  • Dental revenue increased 75.4%, driven by the acquisition of Hu-Friedy, while organic revenue decreased 3.1% due to deferred elective procedures which was slightly offset by strong performance in face masks, face shields, surface disinfectants and wipes
  • Medical revenue decreased 21.7% on an organic basis, with most endoscopy procedures being deferred or delayed during the last five weeks of the quarter
  • Management instituted key cost and cash saving measures which include the following:
    • Deployed workforce furloughs across manufacturing sites experiencing declines in demand, along with temporary furloughs and decreases in pay for administrative personnel
    • Deferred all non-essential capital expenditures
    • Cancelled all non-essential travel
    • Reduced inventory in areas where demand has decreased, including aggressive material management to limit purchasing
    • Suspended any dividend through at least October 31, 2021
    • Suspended and reduced executive salaries and Board of Directors compensation
  • Operating Cash increased 42.4% sequentially to $49.3M, with an ending cash balance of $115.8M

The Company further outlined that the last five weeks of disruption due to COVID had a significant impact on their financial results, specifically in the Medical and Dental segments. For illustrative purposes, using the Company's second quarter results as a comparable, non-COVID impacted quarter, the Medical segment declined ~60% while the Dental segment declined ~55% (down ~70% excluding PPE) in the last five weeks of the quarter. Preliminary, unaudited May revenue results showed signs of improvement, with Medical expected to recover to down ~40% and Dental down ~45% compared to the same second quarter baseline. The Company expects fourth quarter revenue to be below the third quarter, with the expectation that daily sales rates will continue to improve through the quarter.

Fotiades added, "While the deferral of elective procedures over the last five weeks of our third quarter have resulted in lower performance, we are encouraged that preliminary sales results for May are showing signs of recovery. We continue to invest in critical aspects of Cantel 2.0. and have been making progress on our previously announced initiatives, which I look forward to discussing more over the next few months."

Conference Call Information:
The Company will hold a conference call to discuss the results for its third quarter ended April 30, 2020 on Thursday, June 4, 2020 at 8:30 a.m. Eastern Time.

To participate in the conference call, dial 1-844-369-8770 (US & Canada) or 1-862-298-0840 (International) approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, June 4, 2020 through midnight on July 3, 2020 by dialing 1-877-481-4010 (US & Canada) or 1-919-882-2331 (International) and using conference ID #: 34733.

An audio webcast will be available via the Cantel website at www.cantelmedical.com. A replay of the presentation will be archived on the Cantel website for those unable to listen live. In addition, the Company will provide a supplemental presentation to complement the conference call. The presentation can be accessed on Cantel's website in the Investor Relations section under presentations.

About Cantel Medical:
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, instruments and instrument reprocessing workflow systems serving the dental industry, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.

For further information, visit the Cantel website at www.cantelmedical.com.

Our estimated unaudited financial results presented above are preliminary and are subject to the close of the quarter, completion of our quarter-end closing procedures and further financial review. The preliminary financial and business information presented herein has been prepared by and is the responsibility of our management and is based upon information available to us as of the date hereof. Our independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial information. Accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. These estimates are not a comprehensive statement of our financial results for this period and should not be viewed as a substitute for interim financial statements prepared in accordance with generally accepted accounting principles. Our actual results may differ from these estimates as a result of the completion of our quarter-end closing procedures, review adjustments and other developments that may arise between now and the time our financial results for the period are finalized.  As a result, investors should exercise caution in relying on this information and should not draw any inferences from this information regarding financial or operating data not provided..

This press release contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operate, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting the foregoing, words or phrases such as "expect," "anticipate," "goal," "project," "intend," "plan," "believe," "seek," "may," "could," "aspire," and variations of such words and similar expressions generally identify forward-looking statements. In addition, any statements that refer to predictions or projections of our future financial performance, anticipated growth, strategic objectives, performance drivers and trends in our businesses, the impacts and recovery from the COVID pandemic, and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions about future events, activities or developments and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict, including the impacts of the COVID-19 pandemic on our operations and financial results, general economic conditions, technological and market changes in the medical device industry, our ability to execute on our strategy, risks associated with operating our international business, including limited operating experience and market recognition in new international markets, changes in United States healthcare policy at both the state and federal level, product liability claims resulting from the use of products we sell and distribute, and risks related to our intellectual property and proprietary rights needed to maintain our competitive position. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Quarterly Reports on Form 10-Q we have filed or will file hereafter, as further updated by our Current Report on Form 8-K dated May 12, 2020. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CANTEL MEDICAL CORP.

Condensed Consolidated Statements of Income

(Unaudited)



Three Months Ended


Nine Months Ended


April 30,


April 30,


2020


2019


2020


2019

Net sales

$

236,933



$

228,552



$

782,677



$

678,679










Cost of sales

135,950



121,675



443,581



361,878










Gross profit

100,983



106,877



339,096



316,801










Expenses:








Selling

38,057



36,077



121,208



103,233


General and administrative

32,133



48,634



149,471



122,527


Research and development

8,349



7,354



23,953



22,355


Total operating expenses

78,539



92,065



294,632



248,115










Income from operations

22,444



14,812



44,464



68,686










Interest expense, net

10,113



2,509



26,082



6,742


Other income, net







(1,313)










Income before income taxes

12,331



12,303



18,382



63,257










Income taxes

(3,456)



4,128



(909)



17,040










Net income

$

15,787



$

8,175



$

19,291



$

46,217










Earnings per common share - diluted

$

0.37



$

0.20



$

0.46



$

1.11










Dividends declared per common share

$



$



$

0.11



$

0.10










Weighted average shares - diluted

42,187,539



41,759,438



42,327,535



41,726,231



(dollar amounts in thousands except share and per share data or as otherwise specified)

 

CANTEL MEDICAL CORP.

Condensed Consolidated Balance Sheets

(Unaudited)



April 30,
2020


July 31,
2019

Assets




Cash and cash equivalents

$

115,766



$

44,535


Accounts receivable, net

147,558



146,910


Inventories, net

185,493



138,234


Prepaid expenses and other current assets

21,790



20,920


Income taxes receivable

15,422



1,197


Right-of-use assets, net

50,005




Property and equipment, net

224,233



185,242


Intangible assets, net

486,325



141,513


Goodwill

653,626



378,109


Other long-term assets

6,722



9,425


Deferred income taxes

5,432



4,281


Total assets

$

1,912,372



$

1,070,366






Liabilities and stockholders' equity




Accounts payable

$

52,986



$

39,450


Compensation payable

32,520



32,762


Accrued expenses

39,478



38,545


Deferred revenue

26,884



27,840


Current portion of long-term debt

29,500



10,000


Income taxes payable

6,298



2,803


Current portion of lease liabilities

10,269




Long-term debt

937,630



220,851


Deferred income taxes

27,607



29,278


Other long-term liabilities

19,030



7,300


Long-term lease liabilities

41,701




Stockholders' equity

688,469



661,537


Total liabilities and stockholders' equity

$

1,912,372



$

1,070,366



(dollar amounts in thousands except share and per share data or as otherwise specified)

 

CANTEL MEDICAL CORP.

Condensed Consolidated Statements of Cash Flows

(Unaudited)



Nine Months Ended April 30,


2020


2019

Cash flows from operating activities




Net income

$

19,291



$

46,217


Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation

22,105



15,455


Amortization

23,952



15,508


Stock-based compensation expense

8,843



11,885


Amortization of right-of-use assets

9,162




Deferred income taxes

(2,822)



(2,671)


Inventory step-up amortization

16,700




Fair value adjustments to contingent consideration

(6,423)




Other non-cash items, net

3,853



263


Changes in assets and liabilities, net of effects of acquisitions/dispositions:




Accounts receivable

26,990



(18,642)


Inventories

(3,514)



(24,671)


Prepaid expenses and other assets

2,653



(4,929)


Accounts payable and other liabilities

(8,608)



13,608


Income taxes

(11,883)



(3,537)


Operating lease liabilities

(7,456)




Net cash provided by operating activities

92,843



48,486






Cash flows from investing activities




Capital expenditures

(26,212)



(75,387)


Proceeds from sale of businesses

2,236



3,053


Acquisitions, net of cash acquired

(721,350)



(40,644)


Net cash used in investing activities

(745,326)



(112,978)






Cash flows from financing activities




Borrowings of long-term debt

400,000




Repayments of long-term debt

(12,125)



(12,707)


Borrowings under revolving credit facility

388,900



50,000


Repayments under revolving credit facility

(32,900)



(7,000)


Debt issuance costs

(9,234)




Finance lease liabilities

(304)




Dividends paid

(4,471)



(4,173)


Purchases of treasury stock

(3,865)



(4,628)


Net cash provided by financing activities

726,001



21,492






Effect of exchange rate changes on cash and cash equivalents

(2,287)



251






Increase (decrease) in cash and cash equivalents

71,231



(42,749)


Cash and cash equivalents at beginning of period

44,535



94,097


Cash and cash equivalents at end of period

$

115,766



$

51,348



(dollar amounts in thousands except share and per share data or as otherwise specified)

SUPPLEMENTARY INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

In evaluating our operating performance, we supplement the reporting of our financial information determined under generally accepted accounting principles in the United States ("GAAP") with certain non-GAAP financial measures including (i) non-GAAP net income, (ii) non-GAAP earnings per diluted share ("EPS"), (iii) earnings before interest, taxes, depreciation, amortization, loss on disposal of fixed assets, and stock-based compensation expense ("EBITDAS"), (iv) adjusted EBITDAS, (v) net debt and (vi) organic sales. These non-GAAP financial measures are indicators of our performance that are not required by, or presented in accordance with, GAAP. They are presented with the intent of providing greater transparency to financial information used by us in our financial analysis and operational decision-making. We believe that these non-GAAP measures provide meaningful information to assist investors, stockholders and other readers of our consolidated financial statements in making comparisons to our historical operating results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.

To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of our past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. The following are examples of the types of adjustments that are excluded: (i) amortization of purchased intangible assets, (ii) acquisition-related items, (iii) business optimization and restructuring-related charges, (iv) certain significant and discrete tax matters and (v) other significant items management deems irregular or non-operating in nature.

Amortization expense of purchased intangible assets is a non-cash expense related to intangibles that were primarily the result of business acquisitions. Our history of acquiring businesses has resulted in significant increases in amortization of intangible assets that reduce our net income. The removal of amortization from our overall operating performance helps in assessing our cash generated from operations including our return on invested capital, which we believe is an important analysis for measuring our ability to generate cash and invest in our continued growth.

Acquisition-related items consist of (i) fair value adjustments to contingent consideration and other contingent liabilities resulting from acquisitions, (ii) due diligence, integration, legal fees and other transaction costs associated with our acquisition program and (iii) acquisition accounting charges for the amortization of the initial fair value adjustments of acquired inventory and deferred revenue. The adjustments of contingent consideration and other contingent liabilities are periodic adjustments to record such amounts at fair value at each balance sheet date. Given the subjective nature of the assumptions used in the determination of fair value calculations, fair value adjustments may potentially cause significant earnings volatility that are not representative of our operating results. Similarly, due diligence, integration, legal and other acquisition costs associated with our acquisition program, including accounting charges relating to recording acquired inventory and deferred revenue at fair market value, can be significant and also adversely impact our effective tax rate as certain costs are often not tax-deductible. Since these acquisition-related items are irregular and often mask underlying operating performance, we exclude these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to past operating performance.

Restructuring-related and business optimization items consist of severance-related costs associated with work force reductions and other restructuring-related activities. Such costs include (i) salary continuation, (ii) bonus payments, (iii) outplacement services, (iv) medical-related premium costs and (v) accelerated stock-compensation costs. Since these restructuring-related and business optimization items often mask underlying operating performance, we exclude these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to past operating performance.

Excess tax benefits and expenses resulting from stock compensation are recorded as an adjustment to income tax expense. The magnitude of the impact of excess tax benefits generated in the future, which may be favorable or unfavorable, are dependent upon our future grants of equity awards, our future share price on the date awards vest in relation to the fair value of awards on grant date and the exercise behavior of our stock award holders. Since these tax effects are largely unrelated to our results and unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS to arrive at our non-GAAP financial measures.

In April 2020, we recorded a discrete tax benefit related to a provision under the recent federal CARES Act, which allowed us to carryback taxable losses up to five years. We also recorded a discrete tax benefit due to the reversal of a valuation allowance related to a previous acquisition. As these items were unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS for fiscal 2020 to arrive at our non-GAAP financial measures.

In January 2020, we completed the disposition of a dental product line. This resulted in a pre-tax loss of $170 through general and administrative expenses for the nine months ended April 30, 2020. Since this loss was irregular, we made an adjustment to our net income and diluted EPS to exclude this loss to arrive at our non-GAAP financial measures.

During the nine months ended April 30, 2019, we recorded specific discrete tax items associated with our international operations that were unrelated to fiscal 2019. As these items were unrepresentative of our normal effective tax rate, we excluded their impact on net income and diluted EPS for fiscal 2019 to arrive at our non-GAAP financial measures.

In November 2018, we completed the disposition of our high purity water business in Canada. This resulted in a pre-tax gain of $1,313 through other income, net for the nine months ended April 30, 2019. Since this gain was irregular, we made an adjustment to our net income and diluted EPS to exclude this gain to arrive at our non-GAAP financial measures.

During the nine months ended April 30, 2019, we recorded an adjustment to a minor litigation matter in our consolidated financial statements. Since these costs are irregular and mask our underlying operating performance, we made an adjustment to our net income and diluted EPS for fiscal 2019 to exclude such costs to arrive at our non-GAAP financial measures.

Three Months Ended April 30, 2020

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, which includes a gain from the change in fair value of contingent consideration associated with the Hu-Friedy acquisition, (iii) business optimization and restructuring-related charges and (iv) tax matters to arrive at non-GAAP net income and non-GAAP diluted EPS.

Three Months Ended April 30, 2019

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, (iii) other business optimization and restructuring-related charges, primarily related to organizational leadership changes (iv) an adjustment to the excess tax effects applicable to stock compensation and (v) tax matters to arrive at non-GAAP net income and non-GAAP diluted EPS.

The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:


Three Months Ended April 30,

(Unaudited)

2020


2019

Net income/Diluted EPS, as reported

$

15,787



$

0.37



$

8,175



$

0.20


Intangible amortization, net of tax(1)

4,343



0.10



3,850



0.09


Acquisition-related items, net of tax(2)

(12,493)



(0.29)



2,047



0.05


Restructuring-related charges, net of tax(3)

4,439



0.11



8,401



0.20


Excess tax effects(4)





434



0.01


Tax matters(4)

(5,283)



(0.13)



59




Non-GAAP net income/Non-GAAP diluted EPS

$

6,793



$

0.16



$

22,966



$

0.55






(1)

Amounts were recorded in general and administrative expenses.

(2)

For the three months ended April 30, 2020, pre-tax acquisition-related items of $15,240 (benefit) were recorded in general and administrative expenses. For the three months ended April 30, 2019, pre-tax acquisition-related items of $47 were recorded in net sales, $394 were recorded in cost of sales and $2,400 were recorded in general and administrative expenses.

(3)

For the three months ended April 30, 2020, pre-tax restructuring-related items of $2,022 were recorded in cost of sales and $1,797 were recorded in general and administrative expenses. For the three months ended April 30, 2019, pre-tax restructuring-related items of $272 were recorded in cost of sales and $9,840 were recorded in general and administrative expenses.

(4)

Amounts were recorded in income taxes.


(dollar amounts in thousands except share and per share data or as otherwise specified)

Nine Months Ended April 30, 2020

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, which includes a gain from the change in fair value of contingent consideration associated with the Hu-Friedy acquisition, (iii) business optimization and restructuring-related charges, (iv) loss on disposition of product line (v) excess tax effects applicable to stock compensation and (vi) tax matters to arrive at non-GAAP net income and non-GAAP diluted EPS.

Nine Months Ended April 30, 2019

We made adjustments to net income and diluted EPS to exclude (i) amortization expense of purchased intangible assets, (ii) acquisition-related items, (iii) other business optimization and restructuring-related charges, (iv) litigation matters, (v) gain on disposition of business, (vi) excess tax effects applicable to stock compensation and (vii) tax matters to arrive at non-GAAP net income and non-GAAP diluted EPS.

The reconciliations of net income and diluted EPS to non-GAAP net income and non-GAAP diluted EPS were calculated as follows:


Nine Months Ended April 30,

(Unaudited)

2020


2019

Net income/Diluted EPS, as reported

$

19,291



$

0.46



$

46,217



$

1.11


Intangible amortization, net of tax(1)

17,331



0.41



11,928



0.29


Acquisition-related items, net of tax(2)

18,105



0.42



4,236



0.10


Restructuring-related charges, net of tax(3)

9,723



0.23



10,486



0.25


Litigation matters(1)





134




Gain on disposition of business, net of tax(4)





(929)



(0.02)


Loss on disposition of product line, net of tax(1)

130








Excess tax effects(5)

559



0.01



(563)



(0.01)


Tax matters(5)

(5,283)



(0.12)



959



0.02


Non-GAAP net income/Non-GAAP diluted EPS

$

59,856



$

1.41



$

72,468



$

1.74






(1)

Amounts were recorded in general and administrative expenses.

(2)

For the nine months ended April 30, 2020, pre-tax acquisition-related items of $16,700 were recorded in cost of sales and $8,780 were recorded in general and administrative expenses. For the nine months ended April 30, 2019, pre-tax acquisition-related items of $351 were recorded in net sales, $486 were recorded in cost of sales and $4,960 were recorded in general and administrative expenses.

(3)

For the nine months ended April 30, 2020, pre-tax restructuring-related items of $4,841 were recorded in cost of sales and $8,630 were recorded in general and administrative expenses. For the nine months ended April 30, 2019, pre-tax restructuring-related items of $272 were recorded in cost of sales and $12,533 were recorded in general and administrative expenses.

(4)

Amounts were recorded in other income, net.

(5)

Amounts were recorded in income taxes.


(dollar amounts in thousands except share and per share data or as otherwise specified)

Reconciliation of Net Income to EBITDAS and Adjusted EBITDAS

We believe EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment have on net income. In particular, acquisitions have historically resulted in significant increases in amortization of purchased intangible assets that reduce net income. Additionally, we regard EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and is a complement to operating income, net income and other GAAP financial performance measures. We define adjusted EBITDAS as EBITDAS excluding the same non-GAAP adjustments to net income discussed above. We use adjusted EBITDAS when evaluating operating performance because we believe the exclusion of such adjustments, of which a significant portion are non-cash items, is necessary to provide the most accurate measure of on-going core operating results and to evaluate comparative results period over period.

The reconciliations of net income to EBITDAS and adjusted EBITDAS were calculated as follows:


Three Months Ended April 30,


Nine Months Ended April 30,

(Unaudited)

2020


2019


2020


2019

Net income, as reported

$

15,787



$

8,175



$

19,291



$

46,217


Interest expense, net

10,113



2,509



26,082



6,742


Income taxes

(3,456)



4,128



(909)



17,040


Depreciation

7,890



5,892



22,105



15,455


Amortization

8,949



4,956



23,952



15,508


Loss on disposal of fixed assets

1,231



529



1,297



1,368


Stock-based compensation expense

3,027



5,722



8,843



11,885


EBITDAS

43,541



31,911



100,661



114,215


Acquisition-related items(1)

(15,595)



2,841



24,597



5,797


Restructuring-related charges(1)

3,780



6,632



13,403



8,871


Gain on disposition of business







(1,313)


Loss on disposition of product line





170




Litigation matters







163


Adjusted EBITDAS

$

31,726



$

41,384



$

138,831



$

127,733






(1)

Excludes stock-based compensation expense.


(dollar amounts in thousands except share and per share data or as otherwise specified)

Net Debt

We define net debt as long-term debt less cash and cash equivalents. Each of the components of net debt appears on our consolidated balance sheets. We believe that the presentation of net debt provides useful information to investors because we review net debt as part of our management of our overall liquidity, financial flexibility, capital structure and leverage.

(Unaudited)

April 30, 2020


July 31, 2019

Long-term debt (excluding debt issuance costs)

$

976,875



$

233,000


Less cash and cash equivalents

(115,766)



(44,535)


Net debt

$

861,109



$

188,465



(dollar amounts in thousands except share and per share data or as otherwise specified)

Reconciliation of Net Sales Growth to Organic Sales Growth

We define organic sales as net sales less (i) the impact of foreign currency translation, (ii) net sales related to acquired businesses during the first twelve months of ownership and (iii) dispositions during the periods being compared. We believe that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior periods. We exclude the effect of foreign currency translation from organic sales because foreign currency translation is not under management's control, is subject to volatility and can obscure underlying business trends. We exclude the effect of acquisitions and dispositions because the nature, size, and number of acquisitions and divestitures can vary dramatically from period to period and can obscure underlying business trends and make comparisons of financial performance difficult.

For the three months ended April 30, 2020, the reconciliation of net sales growth to organic sales growth for total net sales and net sales of our reportable segments were calculated as follows:

(Unaudited)

Net Sales


Medical
Net Sales


Life Sciences
Net Sales


Dental
Net Sales


Dialysis
Net Sales

Net sales growth

3.7

%


(22.6)

%


7.1

%


75.4

%


8.1

%

Impact due to foreign currency translation

0.5

%


0.9

%


0.2

%


%


0.0

%

Sales related to acquisitions

(15.5)

%


%


0.0

%


(78.5)

%


0.4

%

Organic sales growth

(11.3)

%


(21.7)

%


7.3

%


(3.1)

%


8.5

%


(dollar amounts in thousands except share and per share data or as otherwise specified)

For the nine months ended April 30, 2020, the reconciliation of net sales growth to organic sales growth for total net sales and net sales of our reportable segments were calculated as follows:

(Unaudited)

Net Sales


Medical
Net Sales


Life Sciences
Net Sales


Dental
Net Sales


Dialysis
Net Sales

Net sales growth

15.3

%


(5.5)

%


0.1

%


105.3

%


(7.1)

%

Impact due to foreign currency translation

0.5

%


0.8

%


0.0

%


%


0.1

%

Sales related to acquisitions/dispositions

(17.6)

%


%


2.3

%


(101.8)

%


%

Organic sales growth

(1.8)

%


(4.7)

%


2.4

%


3.5

%


(7.0)

%


(dollar amounts in thousands except share and per share data or as otherwise specified)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cantel-medical-reports-financial-results-for-its-third-quarter-fiscal-year-2020-301070471.html

SOURCE Cantel Medical Corp.